Outside the US, we service companies
based in Japan, France, Germany, Italy,
Saudi Arabia, and farther corners of the
world. Our culturally aware attorneys
speak many languages, including
Japanese, French, German, Mandarin,
Korean, Russian, Arabic, Farsi, Chinese.
In life sciences many properties of the drug are not known until after phase 2 or 3 clinical trials, long after the basic patent has published. The properties often do not relate to new indications but properties which impact a drug’s use. The webinar will focus on leveraging these inherent properties to obtain additional patent protection and further the product’s LCM.
These webinars 30 minutes were held on March 2 and 3, 2022 and hosted by Richard Kelly and Elissa Sanford.